Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
178
datasets available to search
ShareScore release 0.9.0
Dataset results
178 results for “Clinical progression”
Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis [ANALYTE: Cytokine or chemokine]
GEO Series GSE32019. Homo sapiens. 556 samples. Type: Protein profiling by protein array.
DeCAF redefines fibroblast states uncovering multidimensional tumor-stroma relationships driving clinical tumor progression and immunotherapy response
GEO Series GSE311789. Homo sapiens. 142 samples. Type: Other; Expression profiling by high throughput sequencing.
IGFBP2 driven glioma progression is prevented by blocking a clinically significant network of integrin, ILK, and NK-kB
GEO Series GSE35467. Homo sapiens. 4 samples. Type: Expression profiling by array.
Hepatic senescence is associated with clinical progression of NAFLD/NASH: Role of BMP4 and its antagonist Gremlin1 (Hepatocytes)
GEO Series GSE200679. Homo sapiens. 8 samples. Type: Expression profiling by high throughput sequencing.
The clinical and molecular characteristics of progressive hypothalamic/optic pathway pilocytic astrocytoma [RNA-Seq]
GEO Series GSE199361. Homo sapiens. 20 samples. Type: Expression profiling by high throughput sequencing.
Autoantibody Epitope Spreading in the Pre-Clinical Phase Predicts Progression to Rheumatoid Arthritis [ANALYTE: ANTIGEN]
GEO Series GSE32016. Homo sapiens. 559 samples. Type: Protein profiling by protein array.
Genome-wide expression kinetics of children with Type 1 diabetes (T1D) -associated autoantibodies or progression towards clinical T1D, compared to healthy matched controls .
GEO Series GSE43488. Homo sapiens. 356 samples. Type: Expression profiling by array.
Clinical progression of clonal hematopoiesis is determined by a combination of mutation timing, clonal fitness, and structure
GEO Series GSE288742. Homo sapiens. 192 samples. Type: Other.
DeCAF redefines fibroblast states uncovering multidimensional tumor-stroma relationships driving clinical tumor progression and immunotherapy response [scRNA-Seq]
GEO Series GSE311788. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
DeCAF redefines fibroblast states uncovering multidimensional tumor-stroma relationships driving clinical tumor progression and immunotherapy response [RNA-Seq]
GEO Series GSE310957. Homo sapiens. 129 samples. Type: Expression profiling by high throughput sequencing.
DeCAF redefines fibroblast states uncovering multidimensional tumor-stroma relationships driving clinical tumor progression and immunotherapy response [Spatial Transcriptomics]
GEO Series GSE311783. Homo sapiens. 7 samples. Type: Other.
Hepatoprotective effects of late-stage clinical drug candidates and dietary intervention in the non-obese CDAA-HFD mouse model of advanced MASH with progressive fibrosis
GEO Series GSE269493. Mus musculus. 81 samples. Type: Expression profiling by high throughput sequencing.
Targeted Sequencing identifies patients with pre-clinical MDS at high risk of disease progression
GEO Series GSE73074. Homo sapiens. 101 samples. Type: Genome variation profiling by SNP array.
Hepatic senescence is associated with clinical progression of NAFLD/NASH: Role of BMP4 and its antagonist Gremlin1 (Visceral adipose cells)
GEO Series GSE200678. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing.
Clinical Evidence Supports a Protective Role for CXCL5 in Coronary Artery Disease Progression in the Elderly
GEO Series GSE90076. Homo sapiens. 249 samples. Type: Expression profiling by array; Genome variation profiling by SNP array.
Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer [RT-PCR]
GEO Series GSE128277. Homo sapiens. 132 samples. Type: Expression profiling by RT-PCR.
Monocytes in Type 1 diabetes families exhibit high cytolytic activity and subset abundances that correlate with clinical progression
GEO Series GSE239501. Homo sapiens. 4 samples. Type: Expression profiling by high throughput sequencing.
Data from: Impact of aspiration pneumonia on the clinical course of progressive supranuclear palsy: a retrospective cohort study
Introduction: Although aspiration pneumonia is the most common complication of progressive supranuclear palsy (PSP), the clinical impact of aspiration pneumonia on disease course and survival has not been fully estimated. Thus, we retrospectively analyzed the prognostic factors and clinical consequences of pneumonia in PSP. Methods: The clinical course of patients with aspiration pneumonia was surveyed. The association between baseline clinical features (2 years from disease onset) and latency to the initial development of pneumonia was investigated using survival time and Cox regression analyses. Results: Ninety patients with a clinical diagnosis of PSP were observed for 5.1±3.8 years (mean±SD), and 22 had aspiration pneumonia. Subsequently, 20 patients (91%) had to discontinue oral feeding entirely and 13 (59%) died, whereas, of 68 patients without pneumonia, only three patients (4%) died. Time to initial development of pneumonia was strongly correlated with survival time (Spearman R = 0.92, P<0.001), with a mean latency of 2.3 years to death. Among baseline clinical features, early fall episodes and cognitive decline were significant predictors of pneumonia (P = 0.001 and P<0.001, respectively, log rank test). Cox regression analysis demonstrated that early fall episodes (adjusted hazard ratio: 3.9, 95% confidence interval: 1.2–12.5, P = 0.03) and cognitive decline (adjusted hazard ratio: 5.2, 95% confidence interval: 1.4–19.3, P = 0.02) independently predicted pneumonia. By contrast, dysphagia was not associated with pneumonia (P = 0.2, log rank test). Conclusion: Initial development of pneumonia indicates an unfavorable clinical course and predicts survival time (mean survival time 2.3 years). Patients with early falls and cognitive decline were at high risk of early development of pneumonia.
Data from: Cognitive reserve and clinical progression in Alzheimer's disease: a paradoxical relationship
Objective: To investigate the relationship between cognitive reserve (CR) and clinical progression across the Alzheimer's disease (AD) spectrum. Methods: We selected 839 Aβ-positive subjects with normal cognition (NC, n=175), mild cognitive impairment (MCI, n=437) or AD dementia (n=227) from the Alzheimer's Disease Neuroimaging Initiative. CR was quantified using standardized residuals (W-scores) from a (covariate-adjusted) linear regression with global cognition (ADAS-Cog 13) as an independent variable-of-interest, and either gray matter volumes or white matter hyperintensity volume as dependent variables. These W-scores, reflecting whether an individual's degree of cerebral damage is lower or higher than clinically expected, were tested as predictors of diagnostic conversion (i.e. NC to MCI/AD dementia, or MCI to AD dementia) and longitudinal changes in memory (ADNI-MEM) and executive functions (ADNI-EF). Results: The median follow-up period was 24 months (interquartile range: 6-42). Corrected for age, sex, APOE4-status and baseline cerebral damage, higher gray matter volume-based W-scores (i.e. greater CR) were associated with a lower diagnostic conversion risk (hazard ratio [HR]= .22, p<.001) and slower decline in memory (β=.48, p<.001) and executive functions (β=.67, p<.001). Stratified by disease stage, we found similar results for NC (diagnostic conversion: HR=.30, p=.038; ADNI-MEM: β=.52, p=.028; ADNI-EF: β=.42, p=.077) and MCI (diagnostic conversion: HR=.21, p<.001; ADNI-MEM: β=.43, p=.003; ADNI-EF: β=.59, p<.001), but opposite findings (i.e. more rapid decline) for AD dementia (ADNI-MEM: β=-.91, p=.002; ADNI-EF: β=-.77, p=.081). Conclusions: Among Aβ-positive individuals, greater CR related to attenuated clinical progression in pre-dementia stages of AD, but accelerated cognitive decline after the onset of dementia.
Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging
ClinicalTrials.gov study NCT03102203. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.